Sichuan Kelun-Biotech Biopharmaceutical revenue and financials
$468.60Change from previous close: −1.97%Absolute change: −$9.40
In the fiscal year ended December 2025, Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.06B (+6.46% year over year). The net loss was ¥381.97M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.46%
- 2025 vs 2024
- Net margin
- -18.6%
- 2024: -13.8%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -180 | -430 | 59.6 | -271 | — |
| Depreciation and amortization | 100 | 91.4 | 75.1 | 67.4 | — |
| Capital expenditure | -126 | -81.1 | -82.3 | -39.0 | — |
| Investing cash flow | 411 | -822 | -1,025 | -32.2 | — |
| Financing cash flow | 1,728 | 1,037 | 2,382 | 313 | — |
| Debt issued | — | — | 0.0 | 363 | 225 |
| Debt repaid | — | 0.0 | -394 | -45.0 | -70.0 |
| Effect of exchange rates | -51.5 | 22.3 | 19.4 | 0.7 | — |
| Net change in cash | 1,959 | -215 | 1,416 | 10.5 | — |
| Free cash flow | -307 | -511 | -22.7 | -310 | — |